Now Reading: AstraZeneca Slides After Wainua Misses Cardiovascular Goal in Late-Stage Trial
-
01
AstraZeneca Slides After Wainua Misses Cardiovascular Goal in Late-Stage Trial
AstraZeneca Slides After Wainua Misses Cardiovascular Goal in Late-Stage Trial
AstraZeneca shares dropped after Wainua failed to reduce cardiovascular deaths and recurrent heart events in a late-stage trial, dragging on the FTSE 100.
AstraZeneca shares fell sharply after Wainua failed to meet the primary cardiovascular endpoint in a late-stage study, weighing heavily on the FTSE 100 and the wider UK pharmaceutical sector.
AstraZeneca PLC (LSE: AZN), together with US partner Ionis Pharmaceuticals, reported that Wainua did not achieve the study’s main objective of reducing cardiovascular deaths and recurrent cardiovascular events. Reuters reported that AstraZeneca shares fell 6.2% on 9 July, while the UK pharmaceutical index declined 4.3%.
The setback contributed to the FTSE 100 closing 0.2% lower at 10,472.5, despite gains in mining and banking shares.
Late-stage trial failures can materially alter revenue expectations, development timelines and capital-allocation decisions. AstraZeneca’s large index weighting also means company-specific clinical news can affect the direction of the wider UK market.
Company details
- Company: AstraZeneca PLC
- Ticker: LSE: AZN
- Partner: Ionis Pharmaceuticals, NASDAQ: IONS
- Drug: Wainua
- Sector: Pharmaceuticals
- Release time: Reuters market report published 9 July 2026, 11:03 UTC
Source: Reuters, based on company trial results and London market data.
Post Disclaimer
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.
Related Posts
Previous Post
Next Post
